哮喘联盟

   摘要
   血源性成纤维细胞来自于骨髓，可表达一些造血祖细胞表面抗原，与未成熟的间质细胞类似，有表型和功能特征。根据宿主对环境刺激的反应及局部细胞的浸润和不同的细胞因子环境，血源性成纤维细胞在组织中有强烈的促炎症反应或促纤维化作用。过敏性哮喘患者在每次过敏原暴露后及病毒感染期间，其成纤维细胞即从骨髓中进入到气道。进入气道的成纤维细胞在Th2淋巴因子的作用下促进炎症反应和病毒复制，从而进一步加重了因呼吸道病毒感染所致的炎症。慢性治疗不足或激素不敏感的哮喘患者，可出现持续性的外周血成纤维细胞计数增高和气道纤维细胞浸润，并且成纤维细胞主要参与促进气道结构异常，从而导致慢性气道阻塞，从而增加患者的不良预后风险。因此，外周血成纤维细胞计数是新发现的哮喘控制、疾病进展的生物标志物，但作为新的预后指标应用于临床，仍有待在大型临床研究中进一步评估。

 

（苏欣 审校）
J Zhejiang Univ Sci B. 2015 Aug;16(8):651-60. doi: 10.1631/jzus.B1500129.

 

Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma.
 

Mattoli S1.
 

Abstract
Bloodborne fibrocytes are cells mobilized from the bone marrow, which express surface antigens commonly ascribed to hematopoietic progenitors and have phenotypic and functional characteristics similar to those of immature mesenchymal cells. They exhibit predominant proinflammatory or profibrotic activities at tissue sites, depending on the host's response to environmental insults and on the characteristics of the cell infiltrate and cytokine milieu. In patients with allergic asthma, fibrocytes egress from the bone marrow and are recruited into the airways after every allergen exposure and during viral infections. Recruited fibrocytes amplify the inflammatory responses driven by T helper type 2 lymphokines and favor viral replication and further inflammation on respiratory virus infections. Persistently elevated blood fibrocyte counts and persisting airway fibrocytosis are present in patients with chronically undertreated or corticosteroid-insensitive asthma, and are linked to an enhanced risk of adverse outcomes because of the major involvement of fibrocytes in the development of structural abnormalities that lead to chronic airflow obstruction in these patients. Consequently, blood fibrocyte count is an emerging biomarker of asthma control and disease progression and its clinical applicability as a new outcome measure deserves further evaluation in large clinical trials.

J Zhejiang Univ Sci B. 2015 Aug;16(8):651-60. doi: 10.1631/jzus.B1500129.